American College

 
News Articles for American College top ^
Nuance Communications, Inc. (NASDAQ: NUAN) today announced that the American College of Radiology (ACR) and Massachusetts General Hospital (MGH) will leverage the Nuance PowerShare Network, the industry’s largest cloud-based medical imaging exchange, to bring clinical guidelines to the radiologist’s workflow and automate the process of collecting and reporting quality measures to meet industry regulations and guidelines.
Sign-up for American College of Radiology and Massachusetts General Hospital to Use Nuance PowerShare Network for Information Exchange with Radiology Community investment picks
The Medicines Company (NASDAQ:MDCO) will be represented at the American College of Emergency Physicians (ACEP) Annual Scientific Assembly in Chicago, which brings together more than 4,000 emergency medical professionals focused on advancing clinical science that improves the care for millions of Americans who seek first-line treatment through emergency rooms across the country’s hospital systems and centers.
Sign-up for The Medicines Company Announces Participation in 2014 American College of Emergency Physicians Scientific Assembly investment picks
2014/11/17
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced they will present data from their Phase 3 study, "BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study,” at the 2014 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP), November 18, in Boston, MA.
Sign-up for Data from EPIRUS’ Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Actavis plc (NYSE: ACT) announced today that the following linaclotide-related data will be presented during the American College of Gastroenterology 2014 Annual Scientific Meeting in Philadelphia, October 17 through October 22, 2014.
Sign-up for Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
Sign-up for Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology investment picks
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol.
Sign-up for AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting investment picks
The Medicines Company (NASDAQ: MDCO) today announced the presentation of the results of the pivotal Phase III clinical trial of the investigational hemostatic agent RAPLIXA™ (fibrin sealant), formerly known as Fibrocaps, at the 100 th Clinical Congress of the American College of Surgeons in San Francisco, CA.
Sign-up for The Medicines Company Announces Presentation of Investigational Hemostatic Agent RAPLIXA™ (fibrin sealant) Phase III FINISH-3 Trial Results at the 2014 Clinical Conference of the American College of Surgeons investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA.
Sign-up for Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today the presentation of initial data from a Phase IIa clinical study in functional dyspepsia with IW-9179, an investigational guanylate cyclase-C (GC-C) agonist designed to target the upper gastrointestinal (GI) tract.
Sign-up for Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting investment picks
WOODCLIFF LAKE, N.J. and SAN DIEGO , Oct.
Sign-up for Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting investment picks
Data from Sublingual Sufentanil Development Program Highlights Analgesic Response Compared to IV Morphine in Young vs Elderly Adult Patients REDWOOD CITY, Calif.
Sign-up for AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting investment picks
- 37 abstracts evaluating HUMIRA and investigational medicines in rheumatologic diseases - New data presented on ABT-122, an investigational novel protein that targets TNF and IL-17 NORTH CHICAGO, Ill.
Sign-up for AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab) investment picks
http://media.marketwire.com/attachments/201411/81703_horizonpharma.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158415&ProfileId=051205&sourceType=1 DUBLIN, IRELAND --
Sign-up for Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
American College
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: American Capital Ventures  |  Next: American Consumers